Robert Bindert Huizinga - 10 Sep 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: EVP of Research
Issuer ticker: AUPH
Reported as of: 10 Sep 2021
Net transaction value: -$687,325
SEC form: 4
Accepted by SEC: 14 Sep 2021, 17:12:23 UTC
Prior SEC filing: 08 Sep 2021
Next SEC filing: 22 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Robert Bindert Huizinga

Key filing fact

Robert Bindert Huizinga filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 14 Sep 2021.

Key facts

This page summarizes Robert Bindert Huizinga's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Sep 2021, 17:12.

Change

Previous filing in this sequence was filed on 08 Sep 2021.
Current net transaction value: -$687,325.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Sale

Transaction value: $99,150
Shares: -5,000
Change %: -3.6%
Price: $19.83
Shares after: 133,592
Date: 10 Sep 2021
Ownership: Direct
Footnotes: F1

AUPH transaction

Common Stock

Sale

Transaction value: $98,800
Shares: -5,000
Change %: -3.7%
Price: $19.76
Shares after: 128,592
Date: 10 Sep 2021
Ownership: Direct
Footnotes: F1

AUPH transaction

Common Stock

Sale

Transaction value: $489,375
Shares: -22,500
Change %: -17%
Price: $21.75
Shares after: 106,092
Date: 14 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .